News

Suboptimal, dissatisfying treatment affects many psoriasis patients


 

FROM JAMA DERMATOLOGY

The authors said that the study had some limitations. The results may have underestimated the data in the general population, because NPF members are more involved in their health care. Also, severity of the disease at the time of the survey may not have been representative of the patients’ disease course, they noted.

"Going forward, it will be important for us to better understand why psoriasis patients are being undertreated and their reasons for treatment dissatisfaction and discontinuation so that, as physicians, we can provide better care to our psoriasis patients," Dr. Takeshita said.

Dr. Armstrong has received research grants or consultant honoraria from Abbott, Amgen, and Janssen. Dr. Takeshita is a former recipient of the National Psoriasis Foundation’s research fellowship in 2011-2012 and 2012-2013.

nmiller@frontlinemedcom.com

On Twitter @naseemsmiller

Pages

Recommended Reading

Venous thromboembolism risk increased with rheumatoid arthritis
MDedge Internal Medicine
Most American RA patients quit biologics after 2 years
MDedge Internal Medicine
Infliximab, IV steroid combos with methotrexate appear comparable in early RA
MDedge Internal Medicine
Combo of smoking while overweight boosts RA incidence
MDedge Internal Medicine
Trochanteric bursitis: Easily misdiagnosed, readily treatable
MDedge Internal Medicine
Tofacitinib rapidly improves RA signs and symptoms
MDedge Internal Medicine
Puffy fingers improves predictiveness of very early systemic sclerosis diagnosis
MDedge Internal Medicine
Meta-analysis: Lateral wedges don’t reduce medial knee OA pain
MDedge Internal Medicine
Switching nonadherent to denosumab improved bone density
MDedge Internal Medicine
Anserine bursitis: Often-overlooked cause of knee pain
MDedge Internal Medicine